James O'donnell

List of Publications by Year
in descending order

144 papers	6,414 citations	81900 39 h-index	74163 75 g-index
144 all docs	144 docs citations	144 times ranked	8250 citing authors

#	Article	IF	Citations
1	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. Blood Advances, 2023, 7, 302-308.	5.2	3
2	Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. Haematologica, 2022, 107, 668-679.	3.5	8
3	Examining international practices in the management of pregnant women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2022, 20, 82-91.	3.8	7
4	von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Advances, 2022, 6, 62-71.	5.2	17
5	Persistent endotheliopathy in the pathogenesis of long COVID syndrome â€•Reply to comment from von Meijenfeldt et al.. Journal of Thrombosis and Haemostasis, 2022, 20, 270-271.	3.8	5
6	Therapeutic implications of ongoing alveolar viral replication in COVID-19. Lancet Rheumatology, The, 2022, 4, e135-e144.	3.9	17
7	Practical treatment guidance for cancer-associated thrombosis â€“ Managing the challenging patient: A consensus statement. Critical Reviews in Oncology/Hematology, 2022, 171, 103599.	4.4	6
8	The von Willebrand factor â€“ ADAMTSâ€13 axis in malaria. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12641.	2.3	5
9	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Advances, 2022, 6, 3735-3745.	5.2	3
10	Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery. ACS Nano, 2022, 16, 5463-5475.	14.6	17
11	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. Haematologica, 2022, 107, 1950-1954.	3.5	3
12	Perspective: The Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within Thrombosed Pulmonary Venules. Stroke, 2022, 53, 2411-2419.	2.0	3
13	von Willebrand disease and von Willebrand factor. Haemophilia, 2022, 28, 11-17.	2.1	3
14	Neutrophils in COVID-19: Not Innocent Bystanders. Frontiers in Immunology, 2022, 13, .	4.8	52
15	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. Journal of Thrombosis and Haemostasis, 2022, 20, 2350-2365.	3.8	18
16	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. Journal of Thrombosis and Haemostasis, 2021, 19, 701-710.	3.8	7
17	von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli. Thrombosis and Haemostasis, 2021, 121, 086-097.	3.4	2
18	Rapid Whole Blood Clot Retraction Assay on Quartz Crystal Microbalance. , 2021, 5, 1-4.		1

#	Article	IF	Citations
19	Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia. Seminars in Thrombosis and Hemostasis, 2021, 47, 183-191.	2.7	3
20	Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 192-200.	2.7	2
21	Prolonged elevation of Dâ€dimer levels in convalescent COVIDâ€19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, 19, 1064-1070.	3.8	142
22	Realâ€world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal followâ€up in a national adult cohort. Haemophilia, 2021, 27, 618-625.	2.1	9
23	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine, 2021, 47, 899-902.	8.2	38
24	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT) â€“ a novel clinicoâ€pathological entity with heterogeneous clinical presentations. British Journal of Haematology, 2021, 195, 76-84.	2.5	42
25	The Biological Significance of von Willebrand Factor O-Linked Glycosylation. Seminars in Thrombosis and Hemostasis, 2021, 47, 855-861.	2.7	10
26	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	3.8	58
27	Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12531.	2.3	18
28	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
29	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. Journal of Clinical Medicine, 2021, 10, 3536.	2.4	5
30	Current practice and registration patterns among United Kingdom Haemophilia Centre Doctorsâ€™ Organisation centers for patients with unclassified bleeding disorders. Journal of Thrombosis and Haemostasis, 2021, 19, 2738-2743.	3.8	9
31	How I treat bleeding disorder of unknown cause. Blood, 2021, 138, 1795-1804.	1.4	18
32	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 2546-2553.	3.8	208
33	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Advances, 2021, 5, 5023-5031.	5.2	6
34	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	5.2	246
35	Correcting dominantâ€negative von Willebrand disease. Journal of Thrombosis and Haemostasis, 2021, 19, 55-57.	3.8	1
36	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVIDâ€19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	2.5	92

#	Article	IF	Citations
37	Recombinant factor IXâ€Fc fusion protein in severe hemophilia B: Patientâ€reported outcomes and healthâ€related quality of life. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12602.	2.3	4
38	Single centre, realâ€world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. Haemophilia, 2021, 27, e690-e697.	2.1	7
39	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	5.2	5
40	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
41	Telehealth for delivery of haemophilia comprehensive care during the COVIDâ€19 pandemic. Haemophilia, 2020, 26, 984-990.	2.1	31
42	Pulmonary intravascular coagulopathy in COVID-19 pneumonia â€“ Authors' reply. Lancet Rheumatology, The, 2020, 2, e460-e461.	3.9	14
43	Low VWF: insights into pathogenesis, diagnosis, and clinical management. Blood Advances, 2020, 4, 3191-3199.	5.2	22
44	Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria. Blood Advances, 2020, 4, 2851-2864.	5.2	25
45	The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood, 2020, 136, 2864-2874.	1.4	75
46	Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. Scientific Reports, 2020, 10, 18366.	3.3	3
47	More on â€˜Association between ABO blood groups and risk of SARSâ€CoVâ€2 pneumoniaâ€™. British Journal of Haematology, 2020, 190, 27-28.	2.5	35
48	Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e437-e445.	3.9	652
49	New developments in von Willebrand disease. British Journal of Haematology, 2020, 191, 329-339.	2.5	27
50	More on COVIDâ€19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	2.5	73
51	Apolipoprotein A-I enhances activated protein C cytoprotective activity. Blood Advances, 2020, 4, 2404-2408.	5.2	7
52	Investigating the clearance of VWF Aâ€domains using siteâ€directed PEGylation and novel Nâ€linked glycosylation. Journal of Thrombosis and Haemostasis, 2020, 18, 1278-1290.	3.8	8
53	Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematology,the, 2020, 7, e553-e555.	4.6	122
54	Biological mechanisms underlying interâ€individual variation in factor VIII clearance in haemophilia. Haemophilia, 2020, 26, 575-583.	2.1	29

#	Article	IF	Citations
55	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	2.5	307
56	Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. EMBO Molecular Medicine, 2020, 12, e12143.	6.9	3
57	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 431-497.	2.3	11
58	Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone. Journal of Thrombosis and Haemostasis, 2019, 17, 426-428.	3.8	0
59	von Willebrand factor promotes wound healing. Blood, 2019, 133, 2553-2555.	1.4	2
60	von Willebrand factor sialylationâ€"A critical regulator of biological function. Journal of Thrombosis and Haemostasis, 2019, 17, 1018-1029.	3.8	30
61	Advances in understanding the molecular mechanisms of venous thrombosis. British Journal of Haematology, 2019, 186, 13-23.	2.5	31
62	Advances in understanding the molecular mechanisms that maintain normal haemostasis. British Journal of Haematology, 2019, 186, 24-36.	2.5	46
63	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	1.4	32
64	Perioperative management of patients with von Willebrand disease. Hematology American Society of Hematology Education Program, 2019, 2019, 604-609.	2.5	14
65	How I treat low von Willebrand factor levels. Blood, 2019, 133, 795-804.	1.4	36
66	Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood, 2019, 133, 1371-1377.	1.4	36
67	Management of combined factor V and factor VIII deficiency in pregnancy. Journal of Obstetrics and Gynaecology, 2019, 39, 271-272.	0.9	4
68	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood, 2018, 131, 911-916.	1.4	54
69	The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease. Seminars in Thrombosis and Hemostasis, 2018, 44, 167-175.	2.7	10
70	A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy. Haemophilia, 2018, 24, e22-e25.	2.1	7
71	Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Seminars in Thrombosis and Hemostasis, 2018, 44, 159-166.	2.7	34
72	Platelets in malaria pathogenesis. Blood, 2018, 132, 1222-1224.	1.4	12

#	Article	IF	Citations
73	von Willebrand factor clearance â€“ biological mechanisms and clinical significance. British Journal of Haematology, 2018, 183, 185-195.	2.5	51
74	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	5.2	79
75	Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma. Blood, 2018, 132, 1223-1223.	1.4	1
76	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1â€“A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 845-855.	2.4	29
77	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	1.4	98
78	Targeting von Willebrand Factorâ€“Mediated Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1590-1591.	2.4	16
79	Microbiome influences von Willebrand factor. Blood, 2017, 130, 393-395.	1.4	3
80	Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters. Thrombosis, 2016, 2016, 1-3.	1.4	5
81	X-linked moyamoya syndrome associated with severe haemophilia A. Haemophilia, 2016, 22, e51-e54.	2.1	12
82	New treatment approaches to von Willebrand disease. Hematology American Society of Hematology Education Program, 2016, 2016, 683-689.	2.5	27
83	Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 855-863.	2.4	23
84	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. Blood, 2016, 127, 1192-1201.	1.4	41
85	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood, 2016, 128, 1959-1968.	1.4	31
86	Emerging roles for hemostatic dysfunction in malaria pathogenesis. Blood, 2016, 127, 2281-2288.	1.4	54
87	N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. Journal of Thrombosis and Haemostasis, 2016, 14, 2446-2457.	3.8	27
88	Measurement of the viscoelastic properties of blood plasma clot formation in response to tissue factor concentration-dependent activation. Analytical and Bioanalytical Chemistry, 2016, 408, 6581-6588.	3.7	14
89	Recurrent lower limb venous thrombosis associated with a congenitally absent infrarenal inferior vena cava. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 57-57.	0.5	1
90	Engineering activated protein C to maximize therapeutic efficacy. Biochemical Society Transactions, 2015, 43, 691-695.	3.4	12

#	Article	IF	Citations
91	Activated protein C Î²-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury. Blood, 2015, 126, 915-919.	1.4	20
92	Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden. Haemophilia, 2015, 21, e498-e500.	2.1	5
93	von Willebrand factor arginine 1205 substitution results in accelerated macrophageâ€dependent clearance in vivo. Journal of Thrombosis and Haemostasis, 2015, 13, 821-826.	3.8	28
94	Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells. Haematologica, 2014, 99, 185-193.	3.5	22
95	The diagnosis and management of von <scp>W</scp>illebrand disease: a <scp>U</scp>nited <scp>K</scp>ingdom <scp>H</scp>aemophilia <scp>C</scp>entre <scp>D</scp>octors <scp>O</scp>rganization guideline approved by the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 453-465.	2.5	297
96	A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. Analyst, The, 2013, 138, 4769.	3.5	23
97	Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. Blood, 2013, 121, 3801-3810.	1.4	63
98	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood, 2013, 122, 4107-4110.	1.4	65
99	A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care. Proceedings of SPIE, 2013, , .	0.8	0
100	Clinical utility gene card for: haemophilia B. European Journal of Human Genetics, 2012, 20, 3-3.	2.8	2
101	Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin. Blood Coagulation and Fibrinolysis, 2012, 23, 98-103.	1.0	1
102	Oral Rivaroxaban for Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 2525-2527.	27.0	2
103	Elevated plasma factor VIII levels in patients with venous thrombosis â€“ Constitutional risk factor or secondary epiphenomenon?. Thrombosis Research, 2012, 129, 105-106.	1.7	5
104	Elevated factor <scp>VIII</scp> levels and risk of venous thrombosis. British Journal of Haematology, 2012, 157, 653-663.	2.5	236
105	The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. Cellular and Molecular Life Sciences, 2012, 69, 717-726.	5.4	49
106	Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. Thrombosis Research, 2011, 128, e125-e129.	1.7	4
107	Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. Thrombosis Research, 2011, 128, e166-e170.	1.7	3
108	Clinical utility gene card for: von Willebrand disease. European Journal of Human Genetics, 2011, 19, 615-615.	2.8	1

#	Article	IF	Citations
109	Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 992-997.	2.8	1
110	Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. Analytical and Bioanalytical Chemistry, 2011, 399, 691-700.	3.7	6
111	Activated Protein C N-Linked Glycans Modulate Cytoprotective Signaling Function on Endothelial Cells. Journal of Biological Chemistry, 2011, 286, 1323-1330.	3.4	30
112	Clinical utility gene card for: Haemophilia A. European Journal of Human Genetics, 2011, 19, 1-3.	2.8	32
113	Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood, 2010, 115, 1472-1474.	1.4	112
114	Expression of terminal Î±2-6â€“linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood, 2010, 115, 2666-2673.	1.4	79
115	Platelet von Willebrand factor â€“ structure, function and biological importance. British Journal of Haematology, 2010, 148, 834-843.	2.5	69
116	Review: Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. Palliative Medicine, 2010, 24, 386-395.	3.1	22
117	Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. Talanta, 2010, 81, 1725-1730.	5.5	16
118	Platelet Factor 4 Impairs the Anticoagulant Activity of Activated Protein C. Journal of Biological Chemistry, 2009, 284, 5869-5875.	3.4	23
119	Severe Plasmodium falciparum Malaria Is Associated with Circulating Ultra-Large von Willebrand Multimers and ADAMTS13 Inhibition. PLoS Pathogens, 2009, 5, e1000349.	4.7	105
120	The protein C Ï‰â€loop substitution Asn2Ile is associated with reduced protein C anticoagulant activity. British Journal of Haematology, 2009, 144, 946-953.	2.5	13
121	Does antithrombotic therapy improve survival in cancer patients?. Blood Reviews, 2009, 23, 129-135.	5.7	26
122	Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood, 2009, 114, 1658-1665.	1.4	113
123	Concentration-dependent roles for heparin in modifying liopolysaccharide-induced activation of mononuclear cells in whole blood. Thrombosis and Haemostasis, 2008, 99, 570-575.	3.4	28
124	Dissociation of Activated Protein C Functions by Elimination of Protein S Cofactor Enhancement. Journal of Biological Chemistry, 2008, 283, 30531-30539.	3.4	38
125	Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagulation and Fibrinolysis, 2008, 19, 689-692.	1.0	32
126	ABO Blood Group Phenotypes and Plasmodium falciparum Malaria: Unlocking a Pivotal Mechanism. Advances in Parasitology, 2007, 65, 1-50.	3.2	56

#	Article	IF	Citations
127	Antithrombin Nagasaki (Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during pregnancy. Blood Coagulation and Fibrinolysis, 2006, 17, 217-220.	1.0	0
128	ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion, 2006, 46, 1836-1844.	1.6	343
129	von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. British Journal of Haematology, 2006, 133, 562-569.	2.5	116
130	Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagulation and Fibrinolysis, 2005, 16, 465-468.	1.0	24
131	Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood, 2005, 105, 1085-1093.	1.4	217
132	Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood, 2005, 106, 1988-1991.	1.4	99
133	Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. Blood Coagulation and Fibrinolysis, 2004, 15, 207-211.	1.0	38
134	Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. British Journal of Haematology, 2003, 121, 928-931.	2.5	7
135	Acquired protein s deficiency in thrombotic thrombocytopenic purpura patients receiving solvent/detergent plasma exchange. British Journal of Haematology, 2003, 122, 518-519.	2.5	11
136	Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. British Journal of Haematology, 2003, 123, 139-141.	2.5	6
137	Title is missing!. Blood Coagulation and Fibrinolysis, 2003, 14, 283-287.	1.0	10
138	Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia. Expert Opinion on Pharmacotherapy, 2002, 3, 1591-1598.	1.8	2
139	Amount ofHAntigen Expressed on Circulating von Willebrand Factor Is Modified by ABO Blood Group Genotype and Is a Major Determinant of Plasma von Willebrand Factor Antigen Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 335-341.	2.4	125
140	Genotype at the Secretor blood group locus is a determinant of plasma von Willebrand factor level. British Journal of Haematology, 2002, 116, 350-356.	2.5	45
141	A Tyr346â†'Cys substitution in the interdomain acidic regional of factor VIII in an individual with factor VIII:C assay discrepancy. British Journal of Haematology, 2002, 118, 589-594.	2.5	46
142	Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. British Journal of Haematology, 2001, 115, 687-691.	2.5	51
143	Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. British Journal of Haematology, 2000, 110, 454-460.	2.5	192
144	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. Journal of Thrombosis and Haemostasis, 0, , .	3.8	5